My bookmarksSign up free
Source

2012/67/EU: Commission Implementing Decision of 3 February 2012 amending Decision 2008/911/EC establishing a list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products (notified under document C(2012) 514) Text with EEA relevance

2012/67/EU: Commission Implementing Decision of 3 February 2012 amending Decision 2008/911/EC establishing a list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products (notified under document C(2012) 514) Text with EEA relevance

Decision 2008/911/EC · Decision · 3 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

Open ↗

Annexes I and II to Decision 2008/911/EC are amended in accordance with the Annex to this Decision.

Supplementary provisions

ANNEXSupplementary provisions

Open ↗

ANNEX Decision 2008/911/EC is amended as follows: (1) in Annex I, the following substance is inserted after Pimpinella anisum L.: ‘ Thymus vulgaris L., Thymus zygis Loefl. ex L., aetheroleum’; (2) in Annex II, the following is inserted after the entry on Pimpinella anisum L.: ‘ COMMUNITY LIST ENTRY ON THYMUS VULGARIS L., THYMUS ZYGIS LOEFL. EX L., AETHEROLEUM Scientific name of the plant Thymus vulgaris L., Thymus zygis Loefl. ex L. Botanical family Lamiaceae Herbal preparation(s) Essential oil obtained by steam distillation from the fresh flowering aerial parts of Thymus vulgaris L., Thymus zygis Loefl. ex L. or a mixture of both species European Pharmacopoeia monograph reference 01/2008:1374 Indication(s) Traditional herbal medicinal product for the relief of symptoms in coughs and colds. The product is a traditional herbal medicinal product for use in the specified indication exclusively based upon long-standing use. Type of tradition European Specified strength Please see “Specified posology” Specified posology Adults and elderly Cutaneous use: in liquid and semi-solid dosage forms in concentrations up to 10 %; apply up to 3 times daily. Use as bath additive: 0,007-0,025 g per litre. Adolescents Use as bath additive: 0,007-0,025 g per litre Children 6-12 years Use as bath additive: 0,0035-0,017 g per litre Children 3-6 years Use as bath additive: 0,0017-0,0082 g per litre One bath every day or every second day. The cutaneous use in children and adolescents under 18 years of age is not recommended (see section “Special warnings and precaution for use”). The use as bath additive in children under 3 years of age is not recommended (see section “Special warnings and precaution for use”). Route of administration Cutaneous use: apply to the chest and the back. Use as a bath additive: recommended temperature of bath: 35-38 °C. Duration of use or any restrictions on the duration of use Duration of a bath: 10-20 minutes. If the symptoms persist longer than 1 week, a doctor or a qualified health care practitioner should be consulted. Any other information necessary for the safe use Contraindications Hypersensitivity to the active substance. Use as bath additive: Full baths are contraindicated in cases of open wounds, large skin injuries, acute skin diseases, high fever, severe infections, severe circulatory disturbances and cardiac insufficiency. Special warnings and precautions for use Cutaneous use: Like other essential oils Thyme oil should not be applied to the face particularly in the nasal area of babies and infants under the age of 2 years because of the risk of a laryngospasm. When dyspnoea, fever or purulent sputum occurs, a doctor or a qualified health care practitioner should be consulted. The use in children and adolescents under 18 years of age is not recommended due to lack of adequate data. Use as bath additive: When dyspnoea, fever or purulent sputum occurs, a doctor or a qualified health care practitioner should be consulted. The use in children under 3 years of age is not recommended because medical advice should be sought and due to lack of adequate data. In cases of hypertension, a full bath should be used with caution. Interactions with other medicinal products and other forms of interaction None reported. Pregnancy and lactation Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended. Effects on ability to drive and use machines No studies on the effect on the ability to drive and use machines have been performed. Undesirable effects Hypersensitivity reactions and skin irritation have been observed. The frequency is not known. If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted. Overdose No case of overdose has been reported. Pharmaceutical particulars [If necessary] Not applicable. Pharmacological effects or efficacy plausible on the basis of long-standing use and experience [If necessary for the safe use of the product] Not applicable.’

Other acts of the same type
Commission Implementing Decision (EU) 2021/871 of 28 May 2021 on the clearance of the accounts of the paying agencies of the United Kingdom concerning expenditure financed by the European Agricultural Guarantee Fund (EAGF) for financial year 2020 and on the reimbursement of appropriations related to financial discipline, carried over from financial year 2020 (notified under document C(2021) 3685) (Only the English text is authentic)Commission Implementing Decision (EU) 2021/872 of 28 May 2021 on the clearance of the accounts of the paying agencies of the United Kingdom concerning expenditure financed by the European Agricultural Fund for Rural Development (EAFRD) for financial year 2020 (notified under document C(2021) 3686) (Only the English text is authentic)Commission Implementing Decision (EU) 2021/873 of 28 May 2021 on the clearance of the accounts of the paying agencies of Member States concerning expenditure financed by the European Agricultural Fund for Rural Development (EAFRD) for financial year 2020 (notified under document C(2021) 3690)Council Decision (CFSP) 2021/855 of 27 May 2021 amending Decision 2013/255/CFSP concerning restrictive measures against SyriaCommission Implementing Decision (EU) 2021/858 of 27 May 2021 amending Implementing Decision (EU) 2017/253 as regards alerts triggered by serious cross-border threats to health and for the contact tracing of passengers identified through Passenger Locator Forms (Text with EEA relevance)Council Implementing Decision (EU) 2021/879 of 27 May 2021 on the appointment of the Chair of the European Insurance and Occupational Pensions Authority (EIOPA)Commission Implementing Decision (EU) 2021/844 of 26 May 2021 terminating the anti-subsidy proceeding concerning imports of certain hot-rolled flat products of iron, non-alloy or other alloy steel originating in TurkeyCommission Implementing Decision (EU) 2021/856 of 25 May 2021 determining the date on which the European Public Prosecutor’s Office assumes its investigative and prosecutorial tasksDecision (EU) 2021/874 of the European Central Bank of 26 May 2021 amending Decision (EU) 2019/1743 on the remuneration of holdings of excess reserves and of certain deposits (ECB/2021/25)Council Decision (EU) 2021/964 of 26 May 2021 on the conclusion of the Voluntary Partnership Agreement between the European Union and the Republic of Honduras on forest law enforcement, governance and trade in timber products to the European UnionCommission Implementing Decision (EU) 2021/1427 of 21 May 2021 on a pilot project to implement the administrative cooperation provisions relating to refusals to grant authorisations set out in Directive (EU) 2021/555 of the European Parliament and of the Council by means of the Internal Market Information System (Text with EEA relevance)Council Decision (CFSP) 2021/813 of 20 May 2021 amending Decision 2014/486/CFSP on the European Union Advisory Mission for Civilian Security Sector Reform Ukraine (EUAM Ukraine)

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

Contents

What to look at next